Date: 2015-05-26
Type of information: Initiation of preclinical development
phase:
Announcement: identification of a drug development candidate
Company: RedXPharma (UK)
Product: Bruton\'s Tyrosine Kinase (BTK) inhibitor
Action
mechanism: kinase inhibitor/Bruton\'s Tyrosine Kinase inhibitor
Disease: blood cancers, autoimmune diseases
Therapeutic area: Autoimmune diseases - Cancer - Oncology
Country:
Trial details:
Latest
news: * On May 26, 2015, RedXPharma announced that its oncology subsidiary has identified a drug development candidate for a potential new treatment for blood cancers and autoimmune diseases by inhibiting Bruton\'s Tyrosine Kinase (\"BTK\"), the enzyme that plays a key role in the development of these illnesses. Blood cancers include leukaemia such as chronic lymphocytic leukaemia and autoimmune diseases include rheumatoid arthritis, lupus and Sjögren\'s syndrome. The candidate is the Company\'s second to be advanced from its innovative development pipeline. The newly identified novel small molecule inhibitor combines best-in-class potency with distinct selectivity profiles targeted at oncology and autoimmune diseases. This inhibitor blocks BTK, an essential element of the B-cell receptor signalling pathway. It is expected to be able to be taken orally as a once daily dose and to act without the negative side-effects that other current BTK inhibitors exhibit.
Redx currently has 13 proprietary drug programs in its pipeline, with five having achieved pre-clinical proof of concept, demonstrating superior performance to competitor drugs. These programs have relevance for respective therapies to treat MRSA, bone tumours, skin, brain, blood, breast, head and neck, and pancreatic cancers. Redx\'s first drug development candidate is a smoothened inhibitor which has potential to treat basal cell carcinoma, the most common form of skin cancer, through topical application.
